4-benzoyl-1,3-dihydro-imidazol-2-one | 77671-35-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-benzoyl-1,3-dihydro-imidazol-2-one
• 英文别名: 4-Benzoyl-1,3-dihydro-imidazol-2-on；4-benzoyl-1,3-dihydro-2H-imidazol-2-one；4-benzoyl-1,3-dihydroimidazol-2-one
• CAS: 77671-35-3
• 化学式: C₁₀H₈N₂O₂
• 分子量: 188.186
• InChiKey: OZURVBJPWKHWFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-benzoyl-1,3-dihydro-imidazol-2-one 在 盐酸 、 溶剂黄146 、 铂 作用下， 生成 2,3-diamino-1-cyclohexyl-propan-1-ol
  参考文献：
  名称：

  US2514380

  摘要：

  公开号：
• 作为产物：
  描述：

  1,3-二氢咪唑-2-酮 、 苯甲酰氯 在 三氯化铝 作用下， 以 硝基苯 为溶剂， 生成 4-benzoyl-1,3-dihydro-imidazol-2-one
  参考文献：
  名称：

  4-Aroylimidazol-2-ones and their use as pharmaceuticals

  摘要：

  以下是上述结构的4-芳基咪唑啉-2-酮类化合物的中文翻译：Ar为2-呋喃基、2-噻吩基或苯基，后者可以选择性地用一个或两个X基团取代；X为卤素、羟基、C.sub.1-4烷基、C.sub.1-4烷氧基、亚甲二氧基、C.sub.1-4烷硫基、C.sub.1-4烷基亚氧基、C.sub.1-4烷基磺醚基、CF.sub.3、--SO.sub.2 N(R.sub.2).sub.2、NR.sub.3 R.sub.4、吡咯啉基、哌啶基、吗啉基、哌嗪基或N'-烷基-哌嗪基，R为氢、C.sub.1-4烷基、C.sub.1-4烷基羰基或苄基；R.sub.1、R.sub.2、R.sub.3和R.sub.4中的每一个均为氢或C.sub.1-4烷基；以及其药学上可接受的盐。

  公开号：

  US04405635A1

文献信息

• Novel aroylimidazolones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0059948A1

  公开（公告）日：1982-09-15

  This invention relates to aroylimidazole-2-ones and their acid and base addition salts as well as their use as cardiotonics in the treatment of cardiac failure.

  本发明涉及甲酰基咪唑-2-酮及其酸和碱加成盐，以及它们作为治疗心力衰竭的强心剂的用途。
• AROYLIMIDAZOLONES FOR THE TREATMENT OF THAUMETOPOEA EXPOSURE
  申请人：Breakthrough Medical Research B.V.

  公开号：EP3763365A1

  公开（公告）日：2021-01-13

  The invention involves the use of aroylimidazolones such as enoximone in the treatment of conditions caused by exposure to the burning hairs of a caterpillar of the genus Thaumetopoea, such as an oak processionary caterpillar. The invention also relates to compositions for use in such treatment, and to a method of treatment of a condition resulting from exposure to urticating hairs of a caterpillar of the genus Thaumetopoea, wherein the method comprises administering an aroylimidazolone or a pharmaceutically acceptable salt thereof to a subject exposed to said urticating hairs.

  本发明涉及将烯诺酮等甲酰亚胺唑酮类药物用于治疗因接触Thaumetopoea属毛虫（如橡树游行毛虫）的灼烧毛而引起的病症。本发明还涉及用于此类治疗的组合物，以及治疗因暴露于Thaumetopoea属毛虫的灼烧毛而导致的病症的方法，其中该方法包括向暴露于所述灼烧毛的受试者施用阿罗酰咪唑酮或其药学上可接受的盐。
• Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
  申请人：BREAKTHROUGH MEDICAL RESEARCH B.V.

  公开号：US10071077B2

  公开（公告）日：2018-09-11

  The invention involves the use of compounds from the class of aroyl-2H-imidazol-2-ones such as enoximone or a pharmaceutically acceptable salt thereof for modulating the immune system involved in a topic and immune-related disorders. In particular, the invention involves the use of (1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-on) or a pharmaceutically acceptable salt thereof. The invention also involves a pharmaceutical composition including aroyl-2H-imidazol-2-on or a pharmaceutically acceptable salt thereof in an active quantity for the treatment of a topic and immune-related disorders, by modulating the immune system involved in a topic and immune-related disorders. Preference is especially given to a pharmaceutical composition in a dosage unit of 5, 10 or 20 mg, based on the quantity of the active ingredient.

  本发明涉及酰基-2H-咪唑-2-酮类化合物（如烯肟酮）或其药学上可接受的盐在调节免疫系统参与主题和免疫相关疾病方面的用途。特别是，本发明涉及（1,3-二氢-4-甲基-5-[4-（甲硫基）苯甲酰基]-2H-咪唑-2-酮）或其药学上可接受的盐的用途。本发明还涉及一种药物组合物，其中包括活性量的阿罗基-2H-咪唑-2-酮或其药学上可接受的盐，用于通过调节涉及某种疾病和免疫相关疾病的免疫系统来治疗某种疾病和免疫相关疾病。根据活性成分的数量，特别优先考虑剂量单位为 5、10 或 20 毫克的药物组合物。
• Specific Force Deficit in Skeletal Muscles of Old Rats Is Partially Explained by the Existence of Denervated Muscle Fibers
  作者：M. G. Urbanchek、E. B. Picken、L. K. Kalliainen、W. M. Kuzon

  DOI：10.1093/gerona/56.5.b191

  日期：2001.5.1

  We tested the hypothesis that denervated muscle fibers account for part of the specific force (sF(0)) deficit observed in muscles from old adult (OA) mammals, Whole muscle force (F-0) was quantified for extensor digitorum longus (EDL) muscles of OA and young adult (YA) rats. EDL muscle sF(0) was calculated by dividing F-0 by either total muscle fiber cross-sectional area (CSA) or by innervated fiber CSA. Innervated fiber CSA was estimated from EDL muscle cross sections labeled for neural cell adhesion molecules, whose presence is a marker for muscle fiber denervation. EDL muscles from OA rats contained significantly more denervated fibers than muscles from YA rats (5.6% vs 1.1% of total CSA), When compared with YA muscle, oil muscle demonstrated deficits of 34.1% for F-0, 28.3% for sF(0), and 24.9 % for sF(0) calculated by using innervated CSA as the denominator, Denervated muscle fibers accounted for 11.3% of the specific force difference between normal YA and OA skeletal muscle, Other mechanisms in addition to denervation account for the majority of the sF(0) deficit with aging.
• 4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents
  作者：Richard A. Schnettler、Richard C. Dage、J. Martin Grisar

  DOI：10.1021/jm00354a017

  日期：1982.12

  A series of 4-aroyl-1,3-dihydro-2H-imidazol-2-ones was synthesized and evaluated for pharmacological activity in the anesthetized dog. Most members of this series produced dose-related increases in cardiac contractile force as well as relatively minor increases in heart rate and decreases in systemic arterial blood pressure that were not blocked by propranolol. In general, 4-methoxy or 4-methylthiobenzoyl substitution afforded compounds of greatest inotropic potency. 1,3-Dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-one (6) was shown to produce a dose-related positive inotropic effect and reverse the depressant effect of pentobarbital on cardiac pump function in the dog heart-lung preparation. The cardiotonic activity of this series may have important utility in the treatment of congestive heart failure. 1,3-Dihydro-4-[4-(methylthio)benzoyl]-5-methyl-2H-imidazol-2-one (17) was chosen for human studies and is currently undergoing clinical trials.